Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy

Although chimeric antigen receptor (CAR) T-cell therapy has shown a high response rate in lymphoma patients, its cost-effectiveness is controversial due to the high price and uncertainty of the clinical evidence. In addition to the high acquisition cost of CAR T-cell therapy, procedure and facility...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Gyeyoung, Shin, Gyeongseon, Bae, SeungJin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9566791/
https://www.ncbi.nlm.nih.gov/pubmed/36231661
http://dx.doi.org/10.3390/ijerph191912366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9566791/
https://www.ncbi.nlm.nih.gov/pubmed/36231661
http://dx.doi.org/10.3390/ijerph191912366

Ejemplares similares